{'fraction_non_alphanumeric': 0.04297224709042077, 'fraction_numerical': 0.03133393017009848, 'mean_word_length': 5.817073170731708, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Thromboxane A2 (TXA2) receptor blockade suppresses monocyte chemoattractant protein‐1 (MCP‐1) expression by stimulated vascular endothelial cells

In a previous study, it was reported that stimulation with a TXA2 receptor agonist, U46619, augments the expression of adhesion molecules by human umbilical vein endothelial cells (HUVEC). In the present study we showed that U46619 augments the expression of MCP‐1 in HUVEC, both at the protein and mRNA levels. Pretreatment with TXA2 receptor antagonists greatly diminishes the extent of tumour necrosis factor‐alpha (TNF‐α)‐, platelet‐activating factor (PAF)‐, or U46619‐induced mRNA accumulation and production of MCP‐1. Protein kinase C (PKC) inhibitors diminish U46619‐induced mRNA accumulation and production of MCP‐1. NAC, which inhibits nuclear factor κB (NF‐κB) activation and activating protein 1 (AP‐1) binding activity, inhibits the expression of MCP‐1 at the protein and mRNA levels. These results indicate that in HUVEC stimulation via the TXA2 receptors augments MCP‐1 production by induction of the NF‐κB and AP‐1 binding activity through the PKC system.